BR112014026182A2 - derivados de indolin-2-ona como inibidores de proteína cinase - Google Patents

derivados de indolin-2-ona como inibidores de proteína cinase

Info

Publication number
BR112014026182A2
BR112014026182A2 BR112014026182A BR112014026182A BR112014026182A2 BR 112014026182 A2 BR112014026182 A2 BR 112014026182A2 BR 112014026182 A BR112014026182 A BR 112014026182A BR 112014026182 A BR112014026182 A BR 112014026182A BR 112014026182 A2 BR112014026182 A2 BR 112014026182A2
Authority
BR
Brazil
Prior art keywords
indolin
derivatives
protein kinase
kinase inhibitors
cancer
Prior art date
Application number
BR112014026182A
Other languages
English (en)
Inventor
Dhananjay Jagtap Ajit
Shiahuy Chen Grace
Chun Wang Hsiao
Wang Chern Ji
Original Assignee
Annji Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annji Pharm Co Ltd filed Critical Annji Pharm Co Ltd
Publication of BR112014026182A2 publication Critical patent/BR112014026182A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

resumo “derivados de indolin-2-ona como inibidores de proteína cinase” uma nova classe de derivados de indolino-2-ona é divulgada. estes compostos são inibidores de proteína cinase que são úteis para tratar doenças hiperproliferativas, tais como câncer. em uma forma de realização da invenção, o câncer é pelo menos um selecionado a partir do grupo que consiste de câncer de pulmão, câncer colorretal, câncer de fígado e leucemia mielomonocítica aguda.
BR112014026182A 2012-04-20 2013-04-03 derivados de indolin-2-ona como inibidores de proteína cinase BR112014026182A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261635931P 2012-04-20 2012-04-20
PCT/US2013/035177 WO2013158373A1 (en) 2012-04-20 2013-04-03 Indolin-2-one derivatives as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
BR112014026182A2 true BR112014026182A2 (pt) 2017-06-27

Family

ID=49380678

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014026182A BR112014026182A2 (pt) 2012-04-20 2013-04-03 derivados de indolin-2-ona como inibidores de proteína cinase

Country Status (13)

Country Link
US (2) US8969361B2 (pt)
EP (2) EP2838538B1 (pt)
JP (2) JP6177879B2 (pt)
KR (2) KR101774861B1 (pt)
CN (2) CN104394868A (pt)
AU (2) AU2013249708B2 (pt)
BR (1) BR112014026182A2 (pt)
ES (2) ES2621257T3 (pt)
IL (2) IL235097A (pt)
IN (2) IN2014MN02105A (pt)
RU (2) RU2642463C2 (pt)
TW (2) TWI458709B (pt)
WO (2) WO2013158367A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014155301A1 (en) * 2013-03-26 2014-10-02 Piramal Enterprises Limited Substituted bicyclic compounds as inhibitors of ezh2
MA43159B1 (fr) 2015-11-06 2020-08-31 Hoffmann La Roche Dérivés d'indoline-2-one
CN106831707B (zh) * 2016-12-28 2019-09-20 杭州市西溪医院 作为c-Met激酶抑制剂的苯并杂环类衍生物及其医疗用途
GB201709456D0 (en) * 2017-06-14 2017-07-26 Ucb Biopharma Sprl Therapeutic agents
US20240067771A1 (en) 2020-12-23 2024-02-29 Basf Se New catalyst for producing polyurethanes
CN113307799B (zh) * 2021-05-21 2022-07-19 大连医科大学 一种检测葡萄糖醛酸转移酶1a1荧光探针及其应用
CN113999221B (zh) * 2021-11-04 2024-04-05 南京中医药大学 6-位取代的吲哚酮衍生物及其医药用途
CN114380802B (zh) * 2022-01-07 2023-11-17 贵州大学 一类含咔唑基咪唑盐类化合物及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT351865B (de) 1977-04-01 1979-08-27 Hoffmann La Roche Akarizide mittel
US5543414A (en) * 1994-07-28 1996-08-06 Syntex (Usa) Inc. Achiral amino acid acyl esters of ganciclovir and its derivatives
DK2020408T3 (da) * 1998-05-29 2013-09-30 Sugen Inc Pyrrol-substitueret 2-indolinon som proteinkinaseinhibitor
CA2399358C (en) 2000-02-15 2006-03-21 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
US20090264494A1 (en) * 2002-10-18 2009-10-22 Board Of Regents, The University Of Texas System Use of neuroprotective 3-substituted indolone compositions
US7105563B2 (en) 2003-10-24 2006-09-12 Schering Aktiengesellschaft Indolinone derivatives and their use in treating disease-states such as cancer
GT200500321A (es) * 2004-11-09 2006-09-04 Compuestos y composiciones como inhibidores de proteina kinase.
WO2006127217A2 (en) * 2005-05-25 2006-11-30 Eli Lilly And Company Cyclopropanecarboxylate esters of acyclovir
EP1926725A4 (en) 2005-09-22 2010-10-06 Scripps Research Inst PROTEIN KINASEINHIBITORS ON ALKOXYINDOLINONE BASE
CN1850794A (zh) * 2006-05-30 2006-10-25 中国医学科学院医药生物技术研究所 3－酰胺基取代苯甲酰脲类化合物及其抗肿瘤作用
MX2009006170A (es) 2006-12-11 2009-06-19 Irmc Llc Compuestos y composiciones como inhibidores de cinasa.
WO2008071573A2 (en) * 2006-12-13 2008-06-19 F. Hoffmann-La Roche Ag Powder formulation for valganciclovir
EP2167465A1 (en) 2007-06-12 2010-03-31 Boehringer Ingelheim International GmbH Indolinone derivatives and their use in treating disease-states such as cancer
US7846793B2 (en) 2007-10-03 2010-12-07 Applied Materials, Inc. Plasma surface treatment for SI and metal nanocrystal nucleation
WO2009111739A2 (en) * 2008-03-07 2009-09-11 Exley Ray W Treatment of herpes virus related diseases
EP2274311A2 (en) * 2008-03-28 2011-01-19 Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Compounds and methods for the treatment of viral infection
UY31929A (es) * 2008-06-25 2010-01-05 Irm Llc Compuestos y composiciones como inhibidores de cinasa
RU2011103189A (ru) * 2008-06-30 2012-08-10 Силин Фармасьютикалз, Инк. (Us) Производные оксиндола
US20100298376A1 (en) * 2009-05-13 2010-11-25 Board Of Regents, The University Of Texas System Use of novel neuroprotective 3-substituted indolone compositions
GB201014374D0 (en) * 2010-08-27 2010-10-13 Univ Greenwich Novel hybrid compounds
WO2012048235A1 (en) * 2010-10-08 2012-04-12 Novartis Ag Vitamin e formulations of sulfamide ns3 inhibitors

Also Published As

Publication number Publication date
JP2015514761A (ja) 2015-05-21
EP2838531A4 (en) 2015-12-16
TW201350485A (zh) 2013-12-16
WO2013158367A1 (en) 2013-10-24
KR20150005600A (ko) 2015-01-14
IN2014MN02105A (pt) 2015-09-11
US20130281451A1 (en) 2013-10-24
WO2013158373A8 (en) 2014-10-30
CN104302287B (zh) 2017-12-26
IN2014MN02107A (pt) 2015-09-11
JP6177879B2 (ja) 2017-08-09
CN104302287A (zh) 2015-01-21
AU2013249708B2 (en) 2017-03-16
EP2838531B1 (en) 2016-09-21
IL235098A0 (en) 2014-12-31
JP6174119B2 (ja) 2017-08-02
RU2627706C2 (ru) 2017-08-10
AU2013249714A1 (en) 2014-11-13
RU2642463C2 (ru) 2018-01-25
KR20150005630A (ko) 2015-01-14
EP2838538A1 (en) 2015-02-25
US8969361B2 (en) 2015-03-03
CN104394868A (zh) 2015-03-04
EP2838531A1 (en) 2015-02-25
AU2013249714B2 (en) 2016-12-15
RU2014145481A (ru) 2016-06-10
TW201343627A (zh) 2013-11-01
WO2013158373A1 (en) 2013-10-24
IL235097A (en) 2017-07-31
US20130281517A1 (en) 2013-10-24
JP2015514762A (ja) 2015-05-21
ES2621257T3 (es) 2017-07-03
KR101774861B1 (ko) 2017-09-05
EP2838538A4 (en) 2015-09-02
KR101778095B1 (ko) 2017-09-13
ES2600467T3 (es) 2017-02-09
EP2838538B1 (en) 2017-03-15
TWI458709B (zh) 2014-11-01
US8946282B2 (en) 2015-02-03
RU2014145480A (ru) 2016-06-10
AU2013249708A1 (en) 2014-11-13
TWI496784B (zh) 2015-08-21

Similar Documents

Publication Publication Date Title
BR112014026182A2 (pt) derivados de indolin-2-ona como inibidores de proteína cinase
CY1122886T1 (el) Αναστολεις βρωμοεπικρατειων
IL255884A (en) Modified nk-92 cells for cancer treatment
MA55064A (fr) Composés utilisés comme inhibiteurs de kinase
EA201391626A1 (ru) Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
CL2015003089A1 (es) Heterociclos biciclicos como inhibidores de fgfr.
MX2016000143A (es) Compuestos triciclicos fusionados de urea como inhibidores de raf quinasa y/o dimero de raf quinasa.
EA201491456A1 (ru) Соединения-ингибиторы raf
PH12016500169A1 (en) Polymorph of syk inhibitors
UY36175A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
CR20140229A (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
PL2922828T3 (pl) Pochodne 4,6-diaminopirymidynowe jako inhibitory bmi-1 w leczeniu raka
EA201370211A1 (ru) Ингибиторы протеинкиназы
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
PH12016501071B1 (en) Serine/threonine kinase inhibitors
NZ711192A (en) Process for making benzoxazepin compounds
EA201590552A1 (ru) Аминохинолины в качестве ингибиторов киназы
BR112012023836A2 (pt) composto tricíclicos e inibidores de pbk contendo os mesmos
EA201792287A1 (ru) Способы лечения рака
EP3329913A4 (en) Composition for inhibiting formation of snare complex, containing myricetin derivatives
MX2016002924A (es) Inhibidores de cinasa a base de eter arilico.
MX2016016507A (es) Composiciones y metodos para tratar canceres.
EA201691999A1 (ru) Новые сульфониламинобензамидные соединения
BR112016003019A2 (pt) composto, composição farmacêutica, método para tratar câncer em um sujeito com necessidade do mesmo, e método para inibir uma desoxicitidina quinase
MX2016000487A (es) Piridina-2-carboxamidas como nematicidas.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements